SynthesisEndocrine2026
Systematic review of multimodal management strategies for Insulinoma-Induced hypoglycaemia: current evidence and future directions.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe most common functional neuroendocrine neoplasms are insulinomas, representing the leading cause of endogenous hyperinsulinemic hypoglycaemia. The management of insulinoma remains a challenge for clinicians, especially when surgery is neither feasible nor curative. This review aims to evaluate hypoglycaemia-relief drugs for insulinoma, focusing on their effectiveness in glycaemic control, potential impact on tumour burden, and safety.
methodsA comprehensive and systematic review of the literature was performed including traditional hypoglycaemia-relief drugs (diazoxide, glucocorticoids and somatostatin analogues) and newer therapies such as everolimus, sunitinib, Peptide Receptor Radionuclide Therapy (PRRT), radiological debulking approaches and chemotherapy regimens. The drug’s half-life, dosing regimen, route of administration, and safety profile were analysed, along with efficacy in glycaemic control and potential reduction in disease burden.
resultsBenign insulinomas are usually effectively managed with surgical resection, which typically results in symptom resolution. However, advanced and aggressive insulinomas often require a multimodal approach based on systemic drugs and/or minimally invasive radiological techniques. Symptom-relief medications (diazoxide and glucocorticoids) can control hypoglycaemia in selected patients, while other agents (somatostatin analogues, everolimus, PRRT, sunitinib, capecitabine/temozolomide chemotherapy, and debulking techniques) can variably improve both glycaemic control and tumour burden.
conclusionAchieving euglycemia in insulinoma patients, particularly those with metastatic disease, is challenging and requires a comprehensive treatment strategy. This review highlights the need for individualised therapy combining hypoglycaemia-relief drugs, surgical options, and advanced treatments to optimise patient outcomes and improve the quality of life. Further studies are essential to determine optimal sequencing and combination therapies to manage both hypoglycaemia and tumour progression effectively.
Indexed as
Identifiers
41629460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.